Adarx Pharmaceuticals (ADRX) closed at $13.23 on November 6, 2026, down 0.5% from the previous close, on volume of 432,177 shares (30-day average 654,958).
Data as of November 6, 2026.
No headlines found.
Globe Newswire (Thu, 1-Oct 4:15 PM ET)
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.
Adarx Pharmaceuticals trades on the NASDAQ stock market under the symbol ADRX.
As of November 6, 2026, ADRX stock price declined to $13.23 with 432,177 million shares trading.
ADRX has a market cap of $1.41 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that ADRX belongs to (by Net Assets): VTI, VXF, VTWO, VTWG, VTWV.
ADRX support price is $12.62 and resistance is $13.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADRX shares will trade within this expected range on the day.
